First patient dosed in Phase 1/2a study with novel immune rejuvenator, a trispecific antibody-fusion protein Two MDX2004 abstracts accepted for poster presentation at SITC Annual Meeting 2025 WESTON, ...

Sometimes the unintended consequences of a treatment can seem worse than the disease. That's certainly the case for patients ...

Pelareorep plus atezolizumab achieves 30% ORR in second-line or later (≥2L) squamous cell anal carcinoma (SCAC) relative to ...

Co., Ltd. ("Fosun Pharma" or "the Group"; SSE: 600196, HKEX: 02196), a leading innovation-driven global healthcare company, announced its financial results for the first three quarters ...

The Department of Social Welfare and Development (DSWD) has stepped in to assist a 72-year-old retiree afflicted with Stage 4 ...

First five patients in Part C (expansion) of THIO-101 Phase 2 clinical trial enrolled in Taiwan and Turkey CHICAGO, (GLOBE ...

In the absence of a nationwide policy, or a national gambling commission to oversee the industry, each state is on its own.

The most common cholesterol drug around might help protect cancer patients from "chemo brain." Statins appeared to protect ...

Over the past decade, subcutaneous formulations of anticancer drugs—originally administered intravenously—have been ...

An international research team led by RMIT University has created tiny particles, known as nanodots, made from a metallic ...

Scientists estimate that about one in five people will develop cancer in their lifetime. Often, the illness takes a toll on ...

Hepatocellular carcinoma (HCC) represents a leading cause of cancer-related mortality globally. The advent of immunotherapy, particularly immune checkpoint ...